Skin whitening Raw Materials powder Tranexamic acid

Related Attributes

Product details

>Click here to get more information

Tranexamic acid powder Usage and Synthesis.

Tranexamic acid, a synthetic derivative of lysine, is a commonly used hemostatic agent in clinical practice. It plays a hemostatic effect by inhibiting the dissolution of fibrin. Tranaminocyclic acid can strongly adsorb lysine-binding sites (LBS) of fibrin affinity sites on plasminase and plasminogen, and inhibit the binding of plasminogen and fibrin, thus strongly inhibiting the fibrin decomposition caused by plasminogen. In addition, the anti-fibrinolytic effect of tranatemic acid was more obvious in the presence of anti-fibrinolytic enzymes such as macroglobulin in serum. It has a bioavailability of 34% and a half-life of 3.1h.

Uses of Tranexamic acid powder.

Tranexamic acid, a synthetic derivative of lysine, is an antifibrinolytic drug with hemostatic properties. Tranaminocyclic acid can strongly adsorb lysine-binding sites (LBS) of fibrin affinity sites on plasminase and plasminogen, and inhibit the binding of plasminogen and fibrin, thus strongly inhibiting the fibrin decomposition caused by plasminogen. In addition, the anti-fibrinolytic effect of tranatemic acid was more obvious in the presence of anti-fibrinolytic enzymes such as macroglobulin in serum. It has a bioavailability of 34% and a half-life of 3.1h.

Pharmacological action of Tranexamic acid.

Tranexamic acid, also known as tranexamic acid, chemical name 4-aminomethyl cyclohexanocarboxylic acid, trade name tosemin. tranexamicacid (tranexamicacid) is a synthetic amino acid anti-fibrinolytic drug, which can competitively inhibit the binding of fibrin lysine and fibrinolytic enzyme, thus inhibiting the cleavage of fibrin clots and producing hemostatic effect. It is mainly used for various bleeding caused by hyperfibrinolysis. Tranatemocyclic acid is a synthetic lysine analogue, which can competitively bind the lysine binding sites on plasminogen and plasminase, thereby competitively inhibiting fibrin degradation, reducing fibrinolytic activity, and promoting coagulation. Theoretically, the use of tranexamic acid may lead to insufficient fibrinolytic activity, which may increase the risk of postoperative thrombotic events.

Why choose us?

HRK Factory

About Shipping